Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with Relapsed or Refractory DLBCL By Ogkologos - December 6, 2024 478 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the STARGLO study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use Aiming to Prevent Cancer Cases, ESMO Campaigns Against the Use of ‘Low-Alcohol’ Labelling in Response to the Council Agreement on the EU’s Wine Package MOST POPULAR Journalist Is Now Cancer-Free After Receiving Diagnosis On Facebook Live November 1, 2019 UK sunburn risk: Third of adults more likely to protect their... August 2, 2021 Substantial Decrease in the Use of Minimally Invasive Surgery for Cervical... May 5, 2021 COVID-19: “It could take months to build research up again” July 1, 2020 Load more HOT NEWS With Two FDA Approvals, Prostate Cancer Treatment Enters the PARP Era News digest – smoking ban, HPV and prostate cancer, genetic testing... Cancer Prevention and Screening Account for Most Cancer Deaths Averted Among... Off Target: Investigating the Abscopal Effect as a Treatment for Cancer
